glp 1 liver fibrosis GLP-1 and Your Liver: What to Monitor While on Semaglutide or Tirzepatide Pleiotropic effects of systemic administration

November 3, 2025: Ozempic Interferes With Medical Imaging Tests, Study Finds A study has found that taking Ozempic and other GLP-1 receptor agonists can cause issues with medical imaging tests (like PET scans)

Seven drugs have currently been approved for the treatment of Type 2 diabetes mellitus, including short-acting agents like exenatide and lixisenatide, as well as long-acting injectable agents such as albiglutide, dulaglutide, liraglutide, and semaglutide. GLP-1s regulate lipid metabolism, reducing the effects of hyperlipidemia and helping to lower the risk for both chronic kidney disease (CKD) and diabetic kidney disease. They have also been shown to reduce oxidative stress, which includes stimulating glomerular filtration and reducing vasoconstriction, slowing the progression of CKD. Limited data from clinical trials have been published on the effects of GLP-1 receptor agonists in individuals with post-liver transplant diabetes mellitus (PTDM)

Diabetes Care, 28 , 21302135

At the same time, the delivery is moving from weekly injections to daily pills, with better tolerability, reduced cost, and demonstrated cardiovascular benefit on top of weight loss

The demographic of those aged 80 years and above is expanding at an even faster rate

Albiglutide, a long-acting GLP-1 receptor agonist, improves glycemia in type 2 diabetes: time-course analysis [abstract]